Rosacea (Facial Erythema & Inflammatory Rosacea) Treatment
Covered by Aetna in California

For papulopustular (inflammatory) rosacea: topical metronidazole 0.75% gel or 1% gel applied once or twice daily to affected areas after cleansing; for moderate papulopustular rosacea or erythematotelangiectatic component, add generic doxycycline 40–100 mg daily (anti-inflammatory dose) for 8–12 weeks, then reassess; broad-spectrum mineral sunscreen (SPF 30+, zinc oxide or titanium dioxide) used daily — both a treatment adjunct and the primary trigger prevention strategy

Generic azelaic acid 15% gel (Finacea generic) twice daily — FDA-approved for papulopustular rosacea, also addresses post-inflammatory erythema; ivermectin 1% cream (generic Soolantra) once daily — FDA-approved, targets Demodex mite-driven inflammation, first-line alternative per AAD for inflammatory rosacea; for persistent centrofacial erythema unresponsive to anti-inflammatory therapy: brimonidine 0.33% gel once daily (alpha-1 agonist, vasoconstricts superficial vessels, effect lasts ~8–12 hours) or oxymetazoline 1% cream (Rhofade) once daily; for moderate-to-severe papulopustular disease, sub-antimicrobial doxycycline 40 mg modified-release (Oracea) is FDA-approved and avoids resistance concerns — subject to step therapy; encapsulated benzoyl peroxide 5% cream (Epsolay) — newer FDA-approved option for papulopustular rosacea with reduced irritation

Yes (generic agents) — generic metronidazole gel 0.75% typically $15–$40 (120 mL); generic doxycycline hyclate 100 mg typically $4–$15; generic azelaic acid 15% gel $20–$60; generic ivermectin cream $30–$80. Branded products (Oracea, MetroGel, Soolantra branded) require step therapy through generics first; if step therapy met, PA required with prior generic trial documentation.

Per AAD rosacea treatment guidance and clinical literature, rosacea management must address the specific subtype: erythematotelangiectatic rosacea (ETR — flushing, persistent erythema, telangiectasias) requires vasoconstrictors or vascular laser therapy (in-person); papulopustular rosacea (PPR — inflammatory papules and pustules) responds to topical metronidazole, azelaic acid, or ivermectin ± oral doxycycline; phymatous rosacea (rhinophyma) requires in-person surgical or laser management. Sun exposure is the most consistently reported rosacea trigger — UV radiation stimulates TLR2-mediated innate immune activation, promotes neoangiogenesis, and worsens both erythema and inflammatory lesions. Mineral sunscreen with zinc oxide or titanium dioxide is preferred over chemical sunscreens in rosacea because chemical UV-absorbers can cause stinging in sensitive rosacea-prone skin.

Based on Aetna's Rosacea Products Policy (1485-E UDR 07-2024), step therapy specifically requires generic topical metronidazole or generic doxycycline 40 mg as initial step agents before branded products are covered. Ivermectin cream is listed on the Aetna 2026 Drug Guide as a generic — meaning generic ivermectin (the Soolantra equivalent) is available and can be prescribed directly without step therapy. If branded Soolantra is requested and generic ivermectin is available, Aetna would be expected to process the generic formulation without PA. Dr. Bhavsar will prescribe the generic ivermectin formulation to ensure immediate coverage without delays.

Oracea (doxycycline 40 mg modified-release) is subject to Aetna CA step therapy under Policy 1485-E — you must have filled a 30-day supply of generic topical metronidazole or generic doxycycline 40 mg within the prior 120 days before Oracea is automatically covered. Alternatively, you can get prior authorization if you've had an inadequate response to or intolerance of generic metronidazole or generic doxycycline. The clinical appeal of Oracea over standard doxycycline is its anti-inflammatory (not antibiotic) dosing, reducing antibiotic resistance concern — though generic sub-antimicrobial doxycycline 40 mg has the same pharmacological profile and is the required first-step drug. Dr. Bhavsar documents your clinical course to support Oracea PA if needed.

Sunscreen is non-negotiable for rosacea — UV exposure is the most commonly reported trigger, worsening both the erythema and inflammatory components. For rosacea-prone skin, mineral sunscreens (zinc oxide or titanium dioxide, fragrance-free, no alcohol) are strongly preferred over chemical sunscreens. Chemical UV-absorbing ingredients (oxybenzone, avobenzone, octinoxate) generate heat as they absorb UV radiation and cause stinging in sensitive rosacea skin. Tinted mineral formulas with iron oxide are ideal — the iron oxide blocks visible light, which also triggers flushing in some patients. Brands like EltaMD UV Clear, La Roche-Posay Anthelios Mineral, and Neutrogena Sheer Zinc are widely available at California Walgreens, CVS, and Target locations.

Mild ocular rosacea (gritty or burning eye sensation, mild eyelid inflammation/blepharitis) can be assessed and initial management discussed via telehealth — warm compresses, lid hygiene, omega-3 fatty acid supplementation, and systemic doxycycline (which also treats ocular rosacea) can be initiated. However, moderate-to-severe ocular rosacea — significant conjunctival injection, corneal involvement, photophobia, or visual symptoms — requires in-person evaluation by an ophthalmologist to rule out corneal damage, which is a vision-threatening complication of untreated ocular rosacea. TDMD will make an urgent ophthalmology referral when these features are present.

Yes. Aetna commercial plans cover telehealth visits for Rosacea (Facial Erythema & Inflammatory Rosacea) in California. TeleDirectMD (Dr. Parth Bhavsar, MD, NPI: 1104323203) is an in-network telehealth provider with Aetna in California. Your standard Aetna telehealth copay applies — typically $10–$40 for most commercial plans. If clinically appropriate, your prescription is sent to your California pharmacy immediately after your visit.

Most Aetna commercial plans in California have telehealth copays of $10–$40. Often $0–$20 for employer plans. Your exact cost depends on your specific plan and whether your deductible has been met. Log into your Aetna member portal or call the member services number on your card to verify your telehealth copay before your rosacea treatment visit. Self-pay is always available for a flat $49 if you prefer to skip insurance.

If your specific Aetna plan is not in-network with TeleDirectMD in California, or if your deductible has not yet been met, you can book as a self-pay patient for a flat $49 fee — same physician, same quality of care, no insurance needed. You may also be eligible to submit an out-of-network claim to Aetna for partial reimbursement depending on your plan's out-of-network benefit.

TeleDirectMD typically offers same-day and next-day video visits. Book at teledirectmd.com/book-online and select a time that works for you. Most patients are seen within a few hours of booking during business hours. Your rosacea treatment symptoms are evaluated by Dr. Bhavsar, MD — not a nurse practitioner or PA — ensuring you receive a board-certified clinical assessment.

Yes. TeleDirectMD is operated by Dr. Parth Bhavsar, MD (NPI: 1104323203), a board-certified Family Medicine physician. TeleDirectMD is LegitScript certified, HIPAA compliant, and is contracted as an in-network telehealth provider with Aetna in California. Claims are billed using standard CPT codes (99213/99214) and submitted electronically to Aetna.

Yes. Telehealth visits with a licensed physician are qualified medical expenses eligible for FSA (Flexible Spending Account) and HSA (Health Savings Account) payment. If your Aetna plan applies your deductible first, your FSA or HSA card can be used to pay your portion. The $49 self-pay option is also FSA/HSA eligible.